Drug Trial Radar · NCT07207395
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Apr 29, 2025
Primary completion
Oct 2027
Study completion Oct 2028
Sponsor
- Lead sponsor
- The Christ HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.
Conditions
- Lung Cancer (NSCLC)
Interventions
JBI-802Drug
LSD1/HDAC6 Inhibitor
PembrolizumabDrug
PD-1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse EventsTime frame: Up to 28 days after last dose of study drug
- Investigator Assessed ORRTime frame: Up to 28 days from last dose of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Christ Hospital
Cincinnati, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.